DEFA1 and cancer: Besides the discovery of neutrophil defensin 1, 2 and 3 as additional biomarkers for a better classification of responding patients, we also demonstrated that neutrophil defensin 1, 2 and 3 contribute in activation of the immune response towards cancer cells, which could provide a new lead towards an anticancer therapy.